Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

[JAX] [PDX] [J000106574] Acute Leukemia

ABSTRACT:

SUBMITTER:

PROVIDER: S-CMO9725 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

PDX models reflect the proteome landscape of pediatric acute lymphoblastic leukemia but divert in select pathways.

Project description: Not available

| S-EPMC7958471 | biostudies-literature

PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia.

Project description: Not available

| S-EPMC8076590 | biostudies-literature

Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia [PDX shMFN2]

Project description:Mitochondrial metabolism recently emerged as a critical dependency in acute myeloid leukemia (AML). The shape of mitochondria is tightly regulated by dynamin GTPase proteins, which drive opposing fusion and fission forces to consistently adapt bioenergetics to the cellular context. Here, we showed that targeting mitochondrial structure through the inhibition of mitochondrial fusion was a new vulnerability of AML cells, when assayed in patient-derived xenograft (PDX) models. Genetic depletion of mitofusin 2 (MFN2) or optic atrophy 1 (OPA1) or pharmacological inhibition of OPA1 (MYLS22) blocked mitochondrial fusion and had significant anti-leukemic activity, while having limited impact on normal hematopoietic cells ex vivo and in vivo. Mechanistically, inhibition of mitochondrial fusion disrupted mitochondrial respiration and reactive oxygen species production, leading to cell cycle arrest at the G0/G1 transition. These results nominate the inhibition of mitochondrial fusion as a promising therapeutic approach for AML.

2023-03-16 | GSE222167 | GEO

Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia [PDX shOPA1]

2023-03-16 | GSE222168 | GEO

[JAX] [PDX] [J000096913] Acute Leukemia

Project description: Not available

| S-CMO10082 | biostudies-other

PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia.

Project description: Not available

| S-EPMC6284381 | biostudies-literature

Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia [PDX MFN2 OE]

2023-03-16 | GSE222166 | GEO

Acute myeloid leukemia cells resist chemotherapy through a transient senescence-like state [PDX]

Project description:In acute myeloid leukemias (AML), chemotherapy is frequently followed by disease relapse, yet the mechanism by which AML reemerges is not fully understood. We hypothesized that chemotherapy induces senescence-like dormancy that facilitates survival to genotoxic exposure, allowing AML cells to endure treatment in a transiently dormant state while retaining potential for leukemic repopulation. Here, we show that primary AML cells exhibit hallmark senescence features following treatment with cytarabine (AraC), including growth arrest, increased cellular granularity, senescence-associated-β-galactosidase (SA-β-gal) activity, and senescence-associated transcriptomic alterations. Induction of AraC-induced premature senescence was regulated by the ATR kinase activity and mediated stress-survival. High-throughput single cell RNA (scRNA)-seq analysis of primary AML cells ex vivo and in vivo following chemotherapy suggest active transcriptional programming towards senescent-like dormancy instead of enrichment for leukemia stem cells (LSCs). scRNA-seq of sorted AraC-induced premature senescent AML cells demonstrated a heterogenous population including a fraction of cells with simultaneous expression of dormancy- and senescence-associated gene signatures. Xenotransplantation of AraC-induced premature senescent AML cells into mice demonstrated that senescent-like AML cells maintain leukemia-repopulating potential. Altogether, we propose a mechanism of AML relapse whereby AML cells tolerate chemotherapy via acquisition of a transient senescent-like state.

2021-03-14 | GSE146592 | GEO

[JAX] [PDX] [J000106124] Acute Myeloid Leukemia

Project description: Not available

| S-CMO9922 | biostudies-other

[JAX] [PDX] [J000106134] Acute Myeloid Leukemia

Project description: Not available

| S-CMO9898 | biostudies-other